PGC-1alpha down-regulation affects the antioxidant response in friedreich's ataxia

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Marmolino, Daniele ^a   Manto, Mario ^a,b   Acquaviva, Fabio ^c   Vergara, Paola ^c   Ravella, Ajay ^a   Monticelli, Antonella ^d   Pandolfo, Massimo ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b FNRS   (Belgium)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; FRATAXIN; HYDROGEN PEROXIDE; IDEBENONE; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; SMALL INTERFERING RNA; ANTIOXIDANT; CYCLIC AMP DEPENDENT PROTEIN KINASE; HEAT SHOCK PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PPARGC1A PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LOCALIZATION; FIBROBLAST; FRIEDREICH ATAXIA; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; ANIMAL; CASE CONTROL STUDY; CELL CULTURE; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; ANTIOXIDANTS; CASE-CONTROL STUDIES; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; FRIEDREICH ATAXIA; HEAT-SHOCK PROTEINS; HUMANS; HYDROGEN PEROXIDE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; PPAR GAMMA; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTORS;

EID: 77956318471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010025     Document Type: Article

References (80)

1. Delatycki M, Williamson R, Forrest S (2000) Friedreich ataxia: an overview. J Med Genet 37: 1-8.
2. Finocchiaro G, Baio G, Micossi P, Pozza G, di Donato S (1988) Glucose metabolism alterations in Friedreich's ataxia. Neurology 38: 1292-6.
3. Filla A, De Michele G, Coppola G, Federico A, Vita G, et al. (2000) Accuracy of clinical diagnostic criteria for Friedreich's ataxia. Mov Disord 15: 1255-8.
4. Pandolfo M (2003) Friedreich ataxia Semin Pediatr. Neurol Sep 10: 163-72.
5. Pandolfo M (2006) Friedreich ataxia. In Genetic Instabilities and Neurological Diseases 2: 277-298.
6. Shapcott D, Melancon S, Butterworth R, Khoury K, Collu R, et al. (1976) Glucose and insulin metabolism in Friedreich's ataxia. Can J Neurol Sci 3: 361-4.
7. Filla A, de Michele G, Caruso G, Marconi R, Campanella G (1990) Genetic data and natural history of Friedreich's disease: a study of 80 Italian patients. J Neurol 237: 345-51.
8. Campuzano V, Montermini L, Molto MD, Pianese L, Cossée M, et al. (1996) Friedreich ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427.
9. Sakamoto N, Chastain PD, Parniewski P, Ohshima K, Pandolfo M, et al. (1999) Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol Cell 3: 465-475.
10. Grabczyk E, Mancuso M, Sammarco M (2007) A persistent RNA/DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35: 5351-9.
11. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, et al. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2: 551-558.
12. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, et al. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.PLoS ONE 3: 1958.
13. Cossée M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, et al. (2000) Inactivation of the Friedreich ataxiamouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9: 1219-1226.
14. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, et al. (1997) Regulation of mitochondrial iron accumulation by Yfh1, a putative homolog of frataxin. Science 276: 1709-1712.
15. Bou-Abdallah F, Adinolfi S, Pastore A, Laue TM, Chasteen ND (2004) Iron binding and oxidation properties of the bacterial frataxin CyaY of Escherichia coli. J Mol Biol 341: 605-615.
16. Cook JD, Bencze KZ, Jankovic AD, Crater AK, Busch CN, et al. (2006) Monomeric yeast frataxin is an iron binding protein. Biochemistry 45: 7767-7777.
17. Nichol H, Gakh O, O'Neill HA, Pickering IJ, Isaya G, et al. (2003) Structure of frataxin iron cores: an Xray absorption spectroscopic study. Biochemistry 42: 5971-5976.
18. Park S, Gakh O, O'Neill HA, Mangravita A, Nichol H, et al. (2003) Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem 278: 31340-31351.
19. Karlberg T, Schagerlof U, Gakh O, Park S, Ryde U, et al. (2006) The structures of frataxin oligomers reveal the mechanism for the delivery and detoxification of iron. Structure 14: 1535-1546.
20. Rouault TA, Tong WH (2005) Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6: 345-351.
21. Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett 411: 373-7.
22. Bird AJ (2008) Metallosensors, the ups and downs of gene regulation. Adv Microb Physiol 53: 231-267.
23. Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2: 406-414.
24. Tan G, Napoli E, Taroni F, Cortopassi G (2003) Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 12: 1699-1711.
25. Yoon T, Cowan JA (2004) Frataxin mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem 279: 25943-25946.
26. Martelli A, Wattenhofer-Donzé M, Schmucker S, Bouvet S, Reutenauer L, et al. (2007) Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues. Hum Mol Genet [doi 10.1093/hmg/ddm163].
27. Huynen MA, Snel B, Bork P, Gibson TJ (2001) The phylogenetic distribution of frataxin indicates a role in ironsulfur cluster protein assembly. Hum Mol Genet 10: 2463-2468.
28. Santos M, Ohshima K, Pandolfo M (2001) Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum Mol Genet 10: 1935-1944.
29. Piemonte F, Pastore A, Tozzi G, Tagliacozzi D, Santorelli FM, et al. (2001) Glutathione in blood of patients with Friedreich's ataxia. Eur J Clin Invest 31: 1007-11.
30. Bulteau AL, Dancis A, Gareil M, Montagne JJ, Camadro JM, et al. (2007) Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42: 1561-1570.
31. Jiralerspong S, Ge B, Hudson TJ, Pandolfo M (2001) Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Lett 509: 101-105.
32. Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, et al. (2001) Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 10: 2061-2067.
33. Pianese L, Busino L, De Biase I, De Cristofaro T, Lo Casale MS, et al. (2002) Up-regulation of c-Jun N-terminal kinase pathway in Friedreich's ataxia cells. Hum Mol Genet 11: 2989-2996.
34. Emond M, Lepage G, Vanasse M, Pandolfo M (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55: 1752-1753.
35. Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55: 1719-1721.
36. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, et al. (1999) The Friedreich ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet 8: 425-430.
37. Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, et al. (2009) Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum Mol Genet 18: 2452-61.
38. Marmolino D, Acquaviva F (2009) Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy. Cerebellum 8: 245-59.
39. Esterbauer H, Oberkofler H, Krempler F, Patsch W (1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62: 98-102.
40. Knutti D, Kaul A, Kralli A (2000) A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 20: 2411-2422.
41. Wu Z, Puigserver P, Spiegelman BM (1999) Transcriptional activation of adipogenesis. Curr Opin Cell Biol 11: 689-694.
42. Puigserver P, Spiegelman BM (2003) Peroxisome proliferatoractivated receptorgamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90.
43. Handschin C, Spiegelman BM (2006) Peroxisome proliferator- activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
44. Anderson RM, Barger JL, Edwards MG, Braun KH, O'Connor CE, et al. (2008) Dynamic regulation of PGC-1alpha localization and turnover implicatesmitochondrial adaptation in calorie restriction and the stress response. Aging Cell 7: 101-111.
45. Pessayre D (2007) Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22: S20-S27.
46. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408.
47. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M (2005) PGC- 1{alpha} regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66: 562-573.
48. Spiegelman BM (2007) Transcriptional control of energy homeostasis through the PGC-1 coactivators. Novartis Found Symp 286: 3-6.
49. Olmos Y, Valle I, Borniquel S, Tierrez A, Soria E, et al. (2009) Mutual dependence of Foxo3a and PGC-1alpha in the induction of oxidative stress genes. J Biol Chem 284: 14476-84.
50. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, et al. (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55: 496-504.
51. Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, et al. (2009) TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun 379: 43-8.
52. Wenz T, Diaz F, Spiegelman BM, Moraes CT (Activation of the PPAR/PGC- 1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.; PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Cantó C, Auwerx J. Curr Opin Lipidol. 2009 Apr;20(2)98-105. Review.
53. Thomson DM, Winder WW (2009) AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf) 196: 147-54.
54. Irrcher I, Ljubicic V, Kirwan AF, Hood DA (2008) AMP-activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS One 3: 3614.
55. Marmolino D, Acquaviva F, Pinelli M, Monticelli A, Castaldo I, et al. (2009) PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy. Cerebellum 8: 98-103.
56. Puccio H, Simon D, Cossée M, Criqui-Filipe P, Tiziano F, et al. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-6.
57. Puccio H (2009) Multicellular models of Friedreich ataxia. J Neurol 1: 18-24.
58. Karthikeyan G, Santos JH, Graziewicz MA, Copeland WC, Isaya G, et al. (2003) Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum Mol Genet 12: 3331-42.
59. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, et al. (2006) GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580-90.
60. Pook MA, Al-Mahdawi S, Carroll CJ, Cossée M, Puccio H, et al. (2001) Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3: 185-93.
61. Lodi R, Tonon C, Calabrese V, Schapira AH (2006) Friedreich's ataxia: from disease mechanisms to therapeutic interventions. Antioxid. Redox Signal 8: 438-43.
62. Tabrizi SJ, Schapira AH (1999) Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 66: 99-110.
63. Rolfe DF, Brown GC (1997) Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 77: 731-758.
64. de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, et al. (2008) Nrf2-induced antioxidant protection: a promising target to counteract ROSmediated damage in neurodegenerative disease? Free Radic Biol Med 45: 1375-83.
65. Pi J, Zhang Q, Fu J, Woods CG, Hou Y, et al. (2009) ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol, [Epub ahead of print].
66. Clark J, Simon DK (2009) Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 11: 509-28.Vin ̃a J, Gomez-Cabrera MC, Borras C, Froio T, Sanchis-Gomar F, Martinez-Bello VE, Pallardo FV (2009) Mitochondrial biogenesis in exercise and in ageing. Adv Drug Deliv Rev 61: 1369-74.
67. Goffart S, Wiesner RJ (2003) Regulation and co-ordination of nuclear gene expression during mitochondrial biogenesis. Exp Physiol 88: 33-40.
68. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98: 115-24.
69. Adhihetty PJ, Uguccioni G, Leick L, Hidalgo J, Pilegaard H, et al. (2009) The role of PGC-1alpha on mitochondrial function and apoptotic susceptibility in muscle. Am J Physiol Cell Physiol 297: C217-25.
70. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, et al. (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA 101: 6570-6575.
71. Paupe V, Dassa EP, Goncalves S, Auchére F, Lönn M, et al. (2009) Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 4: 4253.
72. Arany Z, He H, Lin J, Hoyer K, Handschin C, et al. (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271.
73. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, et al. (2005) PGC- 1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 3: 101.
74. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119: 121-135.
75. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, et al. (2003) Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem 278: 26597-26603.
76. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M (2005) PGC- 1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66: 562-573.
77. Lotte L, Lyngby SS, Wojtasewski JF, Pilegaard H (2010) PGC-1alpha is required for training-induced prevention of age-associated decline in mitochondrial enzymes in mouse skeletal muscle. Exp Gerontol Jan 18: [Epub ahead of print].
78. Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008) Activation of the PPAR/ PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8: 249-56.
79. Cantó C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
80. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, et al. (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55: 120-127.